Analytical Data
-
Gene name
RelA/NFkB p65
- Application
-
Alternative Names
(Nuclear factor NF-kappa-B p65 subunit)(Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q04206
-
Expression Region
1-210aa
-
Molecular Weight
27.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RelA, commonly known as NF-κB p65, is a pivotal transcription factor that regulates various biological processes, including inflammation, immune responses, and cell proliferation. Its activation is crucial for the expression of a wide array of genes involved in these processes. Under normal conditions, NF-κB is sequestered in the cytoplasm in an inactive form bound to IκB proteins. Upon cellular stimulation by cytokines, growth factors, and other signals, IκB proteins are phosphorylated and subsequently degraded, allowing NF-κB to translocate to the nucleus and initiate gene transcription. Dysregulation of NF-κB signaling has been implicated in numerous diseases, including cancer, autoimmune disorders, and chronic inflammatory diseases, making it a significant target for therapeutic intervention. The need for engineered RelA/NF-κB p65 recombinant proteins has arisen from the necessity to study its structure, function, and regulatory mechanisms in detail. By producing recombinant p65 proteins, researchers can investigate its binding affinity to DNA, interactions with other proteins, post-translational modifications, and its roles in specific signaling pathways. Consequently, studying this protein provides insights into its dual role as a transcription regulator and its potential as a target for drug development aimed at modulating its activity in pathological conditions. Overall, the research surrounding RelA/NF-κB p65 recombinant proteins is vital for advancing our understanding of its biological implications and developing effective therapeutic strategies against diseases linked to its dysfunction.
